Truist’s Kaila Krum on Medtronic’s Q1, APVC’s Juan Pablo Mas details new investment in Exo
In this week’s DeviceTalks Weekly Podcast, Kaila Krum, managing director at Truist Securities, explains why Medtronic is talking tough about finding new growth. Can the medtech giant pull off CEO Geoff Martha’s pledge to `Go Big or Go Home.”
Juan-Pablo Mas, partner at Action Potential Venture Capital, lends insights on his group’s commitment to EXO (pronounced echo), a maker of a portable ultrasound imaging device that might have somewhat unforeseen therapeutic applications. He also shares his hopes for LatinxVC, a non-profit creating opportunities in venture capital.
Senior Editor Danielle Kirsh and Assistant Editor Sean Whooley pinch hit for Chris Newmarker. Kirsh lays out her plans for this year’s Women in Medtech issue and Whooley walks us through this week’s Top 5 stories (aka Newmarker’s Newsmakers.) Medtronic, Abbott, Boston Scientific, Pelvital, and iRhythm all make the list. But who is number 1?
Juan-Pablo Mas, partner at Action Potential Venture Capital, lends insights on his group’s commitment to EXO (pronounced echo), a maker of a portable ultrasound imaging device that might have somewhat unforeseen therapeutic applications. He also shares his hopes for LatinxVC, a non-profit creating opportunities in venture capital.
Senior Editor Danielle Kirsh and Assistant Editor Sean Whooley pinch hit for Chris Newmarker. Kirsh lays out her plans for this year’s Women in Medtech issue and Whooley walks us through this week’s Top 5 stories (aka Newmarker’s Newsmakers.) Medtronic, Abbott, Boston Scientific, Pelvital, and iRhythm all make the list. But who is number 1?
Activity